SHC — Sotera Health Company

Sotera Health Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: Increased by 9.1% year-over-year to $311 million; 8% growth on a constant currency basis.
• Adjusted EBITDA: Rose 12.2% to $164 million, with adjusted EBITDA margins improving to 52.7%, up 147 basis points from Q3 2024.
• Net Income: $48 million ($0.17 per diluted share), compared to $17 million ($0.06 per diluted share) in Q3 2024.
• Adjusted EPS: Increased to $0.26, up $0.09 from the previous year.
• Debt Reduction: Paid down $75 million in debt, leading to a $13 million annual reduction in interest expense.
• Net Leverage Ratio: Improved to 3.3x from 3.7x at the end of 2024.

2. Strategic Updates and Business Highlights

• Sterigenics: Achieved 9.8% revenue growth, driven by strong performance across core medical device customers.
• Nordion: Revenue surged 22.4%, attributed to reactor harvest schedules and customer delivery timing.
• Nelson Labs: Revenue slightly below expectations but showed segment income growth and margin expansion for the fifth consecutive quarter.
• Regulatory Milestone: Nordion secured a 25-year renewal of its Class 1B operating license, ensuring a reliable supply of Cobalt-60 for sterilization processes.

3. Forward Guidance and Outlook

• Revenue Growth: Maintained full-year constant currency revenue growth outlook of 4.5% to 6%, expecting to land near the midpoint.
• Adjusted EBITDA Growth: Raised outlook to 6.75% to 7.75%, up from the previous range of 6% to 7.5%.
• Nelson Labs: Expected to see mid-single-digit revenue decline for the full year due to challenges in Expert Advisory Services.
• Adjusted EPS Guidance: Increased range to $0.81 to $0.86, reflecting improved EBITDA generation and a favorable tax rate.

4. Bad News, Challenges, or Points of Concern

• Nelson Labs: Experienced a 5% revenue decline, primarily due to a drop in Expert Advisory Services, which is impacted by government funding and FDA inspection delays.
• Expert Advisory Services: Noted a significant headwind affecting top-line growth, estimated at a 10-point impact.
• Q4 Expectations: Anticipated margin pullback in Nelson Labs and a significant revenue decline in Nordion due to timing issues, leading to a less favorable Q4 compared to Q3.

5. Notable Q&A Insights

• Volume Recovery: Consistent performance across Sterigenics and various segments, with expectations for continued volume recovery.
• Litigation Update: Positive developments in ongoing litigation cases, particularly in Georgia, where recent court rulings align with Sotera's defense.
• Government Shutdown Impact: Minimal direct impact on overall business; however, some delays in Expert Advisory Services noted.
• Nordion Margins: Some margin pressure due to a shift in product mix towards lower-margin sales, but overall strong performance expected to continue.
• Future Pricing: Sterigenics pricing remains stable, with potential for gradual improvements as regulatory compliance efforts progress.

Overall, Sotera Health reported a strong quarter with solid growth and improved financial metrics, while facing challenges in specific segments and ongoing litigation matters. The outlook remains positive, with strategic initiatives aimed at sustaining growth and addressing headwinds.